Target intelligence / Profile preview

Ebola virus VP35 protein (VP35)

Target
VP35
Molecular classification
Viral RNA-binding protein, Innate immune antagonist, Polymerase cofactor
01

Overview

Ebola virus VP35 protein is a highly multifunctional structural protein encoded by the Ebola virus, critical for viral replication, transcription, and assembly. It acts as an essential cofactor of the viral RNA-dependent RNA polymerase complex (L protein), facilitates immune evasion by binding double-stranded RNA and antagonizing receptor-mediated interferon signaling, and is indispensable for virulence and pathogenesis in host cells. The VP35 protein contains an N-terminal coiled-coil oligomerization domain and a C-terminal interferon inhibitory (dsRNA-binding) domain, both essential for its function. Disruption of VP35 function attenuates viral replication and pathogenicity, making it a promising—but not yet clinically validated—antiviral drug target.

Other names
Viral protein 35EBOV VP35Filovirus VP35
02

Mechanism of action

Drugs or molecules targeting VP35 generally inhibit its dsRNA binding, disrupt its interaction with polymerase (L protein), and/or block its interferon antagonist function.

03

Biological functions

Suppression of host interferon response (immune evasion)Essential cofactor for viral RNA polymeraseRNA binding and inhibition of dsRNA signalingViral assembly and replication
04

Disease associations

Infection (Ebola virus disease / viral hemorrhagic fever)
05

Safety considerations

Targeting viral proteins such as VP35 has the challenge that viral mutation may lead to resistance.Additionally, specificity is crucial to avoid off-target effects on host factors.
06

Interacting drugs

No clinically approved drugs directly target VP35 as of August 2025. Several inhibitors and experimental compounds have been described in research, with the protein serving as a structure-based antiviral target candidate.
07

Biomarkers

VP35 protein expression or the presence of VP35 mRNA can serve as a marker of Ebola infection, but there are no widely used biomarkers for drug response specifically based on VP35.

Beyond the preview

Go deeper on Ebola virus VP35 protein (VP35).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebola virus VP35 protein (VP35).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call